Search

BackgroundCardiac arrest with subsequent cardiopulmonary resuscitation is common in emergency medicine and is often associated with an unfavorable neurologic outcome. Lactate level corresponds to the severity of tissue hypoxia and damage and thus could be useful in predicting neurologic outcome.ObjectivesTo investigate whether lactate and its clearance can serve as early prognostic biomarkers of neurologic outcome after cardiopulmonary resuscitation.MethodsThis study was a retrospective analysis of 249 patients of the Kliniken Maria Hilf hospital who survived at least 12 hours after cardiac arrest and cardiopulmonary resuscitation between 2012 and 2020. Multivariable logistic regressions were performed to correlate the neurologic outcome with lactate level, lactate clearance, and treatment-related patient data to identify factors that are predictors of neurologic outcome.ResultsA lactate level greater than 4.2 mmol/L at admission was significantly associated with an unfavorable neurologic outcome. Among patients with a lactate level greater than 4.2 mmol/L at admission, lactate clearance at 24 hours after admission that was greater than 80.9% was associated with a significant decrease in the probability of an unfavorable neurologic outcome.ConclusionsThese results suggest that lactate and its clearance have an impact on neurologic outcome and can be used as prognostic biomarkers and in treatment decision-making in patients with cardiac arrest and successful resuscitation.

Extracorporeal carbon dioxide removal (ECCO2R) is increasingly considered a viable therapeutic approach in the management of hypercapnic lung failure to avoid intubation or to allow lung-protective ventilator settings. This study aimed to analyze efficacy and safety of a minimal-invasive ECCO2R device, the Homburg lung. The Homburg lung is a pump-driven system for veno-venous ECCO2R with ¼″ tubing and a 0.8 m surface oxygenator. Vascular access is usually established via a 19F/21 cm bilumen cannula in the right internal jugular vein. For this work, we screened patient registries from two German centers for patients who underwent ECCO2R with the Homburg lung because of hypercapnic lung failure since 2013. Patients who underwent extracorporeal membrane oxygenation before ECCO2R were excluded. Patients who underwent ECCO2R more than one time were only included once. In total, 24 patients (aged 53.86 ± 12.49 years; 62.5% male) were included in the retrospective data analysis. Ventilatory failure occurred because of chronic obstructive pulmonary disease (50%), cystic fibrosis (16.7%), acute respiratory distress syndrome (12.5%), and other origins (20.8%). The system generated a blood flow of 1.18 ± 0.23 liters per minute (lpm). Sweep gas flow was 3.87 ± 2.97 lpm. Within 4 hours, paCO2 could be reduced significantly from 82.05 ± 15.57 mm Hg to 59.68 ± 12.27 mm Hg, thereby, increasing pH from 7.23 ± 0.10 to 7.36 ± 0.09. Cannulation-associated complications were transient arrhythmia (1/24 patients) and air embolism (1/24). Fatal complications did not occur. In conclusion, the Homburg lung provides effective carbon dioxide removal in hypercapnic lung failure. The cannulation is a safe procedure, with complication rates comparable to those in central venous catheter implantation.

Myocardial infarction is a frequent cause of out-of-hospital cardiac arrest. However, the benefits of early coronary angiography and revascularization in resuscitated patients without electrocardiographic evidence of ST-segment elevation are unclear.In this multicenter trial, we randomly assigned 554 patients with successfully resuscitated out-of-hospital cardiac arrest of possible coronary origin to undergo either immediate coronary angiography (immediate-angiography group) or initial intensive care assessment with delayed or selective angiography (delayed-angiography group). All the patients had no evidence of ST-segment elevation on postresuscitation electrocardiography. The primary end point was death from any cause at 30 days. Secondary end points included a composite of death from any cause or severe neurologic deficit at 30 days.A total of 530 of 554 patients (95.7%) were included in the primary analysis. At 30 days, 143 of 265 patients (54.0%) in the immediate-angiography group and 122 of 265 patients (46.0%) in the delayed-angiography group had died (hazard ratio, 1.28; 95% confidence interval [CI], 1.00 to 1.63; P = 0.06). The composite of death or severe neurologic deficit occurred more frequently in the immediate-angiography group (in 164 of 255 patients [64.3%]) than in the delayed-angiography group (in 138 of 248 patients [55.6%]), for a relative risk of 1.16 (95% CI, 1.00 to 1.34). Values for peak troponin release and for the incidence of moderate or severe bleeding, stroke, and renal-replacement therapy were similar in the two groups.Among patients with resuscitated out-of-hospital cardiac arrest without ST-segment elevation, a strategy of performing immediate angiography provided no benefit over a delayed or selective strategy with respect to the 30-day risk of death from any cause. (Funded by the German Center for Cardiovascular Research; TOMAHAWK ClinicalTrials.gov number, NCT02750462.).

The aim of the current paper is to summarize the results of the International CytoSorb Registry. Data were collected on patients of the intensive care unit. The primary endpoint was actual in-hospital mortality compared to the mortality predicted by APACHE II score. The main secondary endpoints were SOFA scores, inflammatory biomarkers and overall evaluation of the general condition. 1434 patients were enrolled. Indications for hemoadsorption were sepsis/septic shock (N = 936); cardiac surgery perioperatively (N = 172); cardiac surgery postoperatively (N = 67) and “other” reasons (N = 259). APACHE-II-predicted mortality was 62.0±24.8%, whereas observed hospital mortality was 50.1%. Overall SOFA scores did not change but cardiovascular and pulmonary SOFA scores decreased by 0.4 [-0.5;-0.3] and -0.2 [-0.3;-0.2] points, respectively. Serum procalcitonin and C-reactive protein levels showed significant reduction: -15.4 [-19.6;-11.17] ng/mL; -17,52 [-70;44] mg/L, respectively. In the septic cohort PCT and IL-6 also showed significant reduction: -18.2 [-23.6;-12.8] ng/mL; -2.6 [-3.0;-2.2] pg/mL, respectively. Evaluation of the overall effect: minimal improvement (22%), much improvement (22%) and very much improvement (10%), no change observed (30%) and deterioration (4%). There was no significant difference in the primary outcome of mortality, but there were improvements in cardiovascular and pulmonary SOFA scores and a reduction in PCT, CRP and IL-6 levels. Trial registration: ClinicalTrials.gov Identifier: NCT02312024 (retrospectively registered).

Emergency medical care for critically ill nontrauma patients (CINT) varies between different emergency departments (ED) and healthcare systems, while resuscitation of trauma patients is always performed within the ED. In many ED CINT are treated and stabilized while in many German smaller hospitals CINT are transferred directly to the intensive care unit (ICU) without performing critical care measures in the ED. Little is known about the resuscitation room management of CINT regarding patient characteristics and outcome although bigger hospitals perform ED resuscitation of CINT in routine care. Against this background we conducted this retrospective analysis of CINT treated by an ED resuscitation room concept in a German 756 bed teaching hospital.The collective of CINT treated within the ED resuscitation room (1 October 2018 to 31 March 2019) was analyzed after ethical approval. After each resuscitation room operation, the team leader filled out a standardized paper-based questionnaire and qualified the patient as a resuscitation room patient this way. Only patients who underwent invasive procedures and were admitted to ICU or died in the ED were included. Patient characteristics, performed critical care measures, short-term outcomes and the comparison of admission characteristics between survivors and non-survivors were evaluated. Additionally, the accordance of ED admission diagnoses and discharge diagnoses were analyzed.Overall, 243 of 19,854 ED patients (1.22%) were treated in the resuscitation room. After exclusion of trauma patients, 193 (0.97%) CINT were included. Overall mortality was 29% (n = 56), 24‑h mortality was 13% (n = 25). Patient characteristics (vital signs, blood gas analysis) differed significantly between survivors and nonsurvivors except for respiratory rate and pain scale. An excerpt of conducted resuscitation room measures was as follows: arterial line n = 78 (40%); noninvasive ventilation n = 60 (31%); endotracheal intubation n = 56 (29%); cardiopulmonary resuscitation n = 19 (10%), central venous line n = 8 (4%). The number of conducted measures differed between survivors and nonsurvivors (median and interquartile range, IQR): 4 (IQR 2) vs. 4 (IQR 3) p = 0.0453. The length of ED stay was 148.2 ± 202.7 min until the patient was admitted to an ICU or died within the ED. ED admission diagnoses matched with hospital discharge diagnoses in 78%.The observed mortality was high and was comparable to patient collectives with septic shock. Nonsurvivors showed significantly more impaired vital parameters and blood gas analysis parameters. Vital parameters together with blood gas analysis might enable ED risk stratification of CINT. Resuscitation room management enables immediate stabilization and diagnostic work-up of CINT even when no ICU bed is available. Furthermore, optimal allocation to specialized ICUs can probably be enabled more accurately after a first diagnostic work-up; however, although a first diagnostic work-up including laboratory tests and computed tomography in many cases was performed, ED admission and hospital discharge diagnoses matched only in 78%.EINLEITUNG: Die Notfallversorgung für kritische Kranke ist in verschiedenen Gesundheitssystemen heterogen organisiert. Während Traumapatienten immer im Schockraum übergeben und stabilisiert werden, erfolgt speziell in der deutschen Grund- und Regelversorgung bei kritisch kranken Nicht-Traumapatienten häufig eine direkte Aufnahme auf die Intensivstation durch den Rettungsdienst. In dieser retrospektiven Studie wurde daher die Schockraumversorgung nichttraumatologischer Patienten in einem 756-Betten-Lehrkrankenhaus analysiert.Schockraumversorgungen kritisch Kranker (01.10.2018 bis 31.03.2019) wurden in Bezug auf Patientencharakteristika, durchgeführte Schockraummaßnahmen und Krankenhaussterblichkeit analysiert. Ferner sollten die Aufnahmecharakteristika zwischen Überlebenden und Nichtüberlebenden evaluiert werden. Aufnahme- und Entlassungsdiagnosen sollten vergleichend ausgewertet werden.Es wurden 243/19.854 Patienten (1,22 %) im Untersuchungszeitraum als Schockraumpatienten behandelt. Nach Ausschluss von Traumapatienten konnten 193 (0,97 %) kritisch kranke nichttraumatologische Patienten eingeschlossen werden. Die Gesamtsterblichkeit lag bei 29 % (n = 56), die 24-h-Sterblichkeit bei 13 % (n = 25). Es wurden im Mittel 4,24 Schockraummaßnahmen (z. B. Intubation, Zentraler Venenkatheter) durchgeführt mit einer Versorgungsdauer in der Notaufnahme von 148 ± 203 min. Die Aufnahmeparameter von Überlebenden und Nichtüberlebenden unterschieden sich signifikant mit Ausnahme von Atemfrequenz und Schmerzskala. Durchgeführte Schockraummaßnahmen bei Überlebenden vs. Nichtüberlebenden: Median 4 (IQR 2) vs. 4 (IQR 3), p = 0,0453. Krankenhausaufnahme- und Entlassungsdiagnosen stimmten in 78 % der Fälle überein.Bei insgesamt hoher Krankenhaussterblichkeit zeigten sich signifikant schlechtere Vital- und Blutgasanalyseparameter bei Aufnahme für das Subkollektiv der Nichtüberlebenden. Ein möglicher Score aus Vital- und Blutgaswerten könnte folglich eine zukünftige Risikostratifizierung für nichttraumatologische Schockraumpatienten ermöglichen. Die nichttraumatologische Schockraumversorgung ermöglicht eine sofortige notfallmedizinische Versorgung und genaue Patientenallokation zu spezialisierten Intensivstationen. Nichtsdestotrotz stimmten Krankenhausaufnahme- und Entlassungsdiagnosen in 78 % überein.

Introduction. Emergency department (ED) triage regarding infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is challenging. During the coronavirus disease 2019 (COVID-19) outbreak in Germany, the diagnostic outcomes of critically ill patients admitted to the resuscitation room in the ED of our academic 754-bed hospital should be analyzed. Methods. All resuscitation room patients between March 1st and April 15th 2020 were included in this retrospective study. Every patient with suspicion of SARS-CoV-2 infection received a pharyngeal swab for real-time polymerase chain reaction (rt-PCR), divided in the clinical subgroups of “highly suspicious for COVID-19” and “COVID-19 as differential diagnosis.” All respiratory and infectious symptoms were included as at least “differential diagnosis” as an expanded suspicion strategy. Results. Ninety-five patients were included (trauma n=14, critically ill n=81). Of 3 highly suspicious patients, 2 had rt-PCR positive pharyngeal swabs. In 39 patients, COVID-19 was defined as differential diagnosis, and 3 were positive for SARS-CoV-2. Of them, pharyngeal swabs were positive in 1 case, while in 2 cases, only tracheal fluid was rt-PCR positive while the pharyngeal swabs were negative. In one of these 2 cases, chest computed tomography (CT) was also negative for ground-glass opacities but showed a pulmonary abscess and pulmonary embolism. Conclusion. We recommend an expanded suspicion strategy for COVID-19 due to unexpected diagnostic outcomes. Personal protective equipment should be used in every resuscitation room operation due to unexpected cases and initial knowledge gaps. Furthermore, tracheal fluid should be tested for SARS-CoV-2 in every intubated patient due to cases with negative pharyngeal swabs and negative chest CT.

Aims: The diagnostic approach to idiopathic giant-cell myocarditis (IGCM) is based on identifying various patterns of inflammatory cell infiltration and multinucleated giant cells (GCs) in histologic sections taken from endomyocardial biopsies (EMBs). The sampling error for detecting focally located GCs by histopathology is high, however. The aim of this study was to demonstrate the feasibility of gene profiling as a new diagnostic method in clinical practice, namely in a large cohort of patients suffering from acute cardiac decompensation. Methods and Results: In this retrospective multicenter study, EMBs taken from n = 427 patients with clinically acute cardiac decompensation and suspected acute myocarditis were screened (mean age: 47.03 &plusmn, 15.69 years). In each patient, the EMBs were analyzed on the basis of histology, immunohistology, molecular virology, and gene-expression profiling. Out of the total of n = 427 patient samples examined, GCs could be detected in 26 cases (6.1%) by histology. An established myocardial gene profile consisting of 27 genes was revealed, this was narrowed down to a specified profile of five genes (CPT1, CCL20, CCR5, CCR6, TLR8) which serve to identify histologically proven IGCM with high specificity in 25 of the 26 patients (96.2%). Once this newly established profiling approach was applied to the remaining patient samples, an additional n = 31 patients (7.3%) could be identified as having IGCM without any histologic proof of myocardial GCs. In a subgroup analysis, patients diagnosed with IGCM using this gene profiling respond in a similar fashion to immunosuppressive therapy as patients diagnosed with IGCM by conventional histology alone. Conclusions: Myocardial gene-expression profiling is a promising new method in clinical practice, one which can predict IGCM even in the absence of any direct histologic proof of GCs in EMB sections. Gene profiling is of great clinical relevance in terms of a) overcoming the sampling error associated with purely histologic examinations and b) monitoring the effectiveness of therapy.

Veno-venous extracorporeal membrane oxygenation (vvECMO) is increasingly used as rescue therapy in severe respiratory failure. In patients with pre-existent lung diseases or persistent lung injury weaning from vvECMO can be challenging. This study sought to investigate outcomes of patients transferred to a specialized ECMO center after prolonged ECMO therapy. We performed a retrospective analysis of all patients admitted to our medical intensive care unit (ICU) between 01/2013 and 12/2016 who were transferred from an external ICU after > 8 days on vvECMO. 12 patients on ECMO for > 8 days were identified. Prior to transfer, patients underwent ECMO therapy for 18 ± 9.5 days. Total time on ECMO was 60 ± 46.6 days. 11/12 patients could be successfully weaned from ECMO, 7/12 in the first 28 days after transfer (8 ± 8.8 ECMO-free days at day 28). In 7 patients, ECMO could be terminated after at least partial lung recovery, in 4 patients after salvage lung transplant. No patient died or needed re-initiation of ECMO therapy at day 28. In summary, weaning from vvECMO was feasible even after prolonged ECMO courses and salvage lung transplant could be avoided in most cases. Patients may benefit from transfer to a specialized ECMO center.

Rationale: Patients with interstitial lung disease and acute respiratory failure have a poor prognosis especially if mechanical ventilation is required.Objectives: To investigate the outcome of patients with acute respiratory failure in interstitial lung disease undergoing extracorporeal membrane oxygenation (ECMO) as a bridge to recovery or transplantation.Methods: This was a retrospective analysis of all patients with interstitial lung disease and acute respiratory failure treated with or without ECMO from March 2012 to August 2015.Measurements and Main Results: Forty patients with interstitial lung disease referred to our intensive care unit for acute respiratory failure were included in the analysis. Twenty-one were treated with ECMO. Eight patients were transferred by air from other hospitals within a range of 320 km (linear distance) for extended intensive care including the option of lung transplant. In total, 13 patients were evaluated, and eight were finally found to be suitable for lung transpla...

Patients experiencing out-of-hospital cardiac arrest (OHCA) without ST-segment elevation are a heterogenic group with a variety of underlying causes. Up to one-third of patients display a significant coronary lesion compatible with myocardial infarction as OHCA trigger. There are no randomized data on patient selection and timing of invasive coronary angiography after admission. METHODS AND RESULTS: The TOMAHAWK trial randomly assigns 558 patients with return of spontaneous circulation after OHCA with no obvious extracardiac origin of cardiac arrest and no ST-segment elevation/left bundle-branch block on postresuscitation electrocardiogram to either immediate coronary angiography or initial intensive care assessment with delayed/selective angiography in a 1:1 ratio. The primary end point is 30-day all-cause mortality. Secondary analyses will be performed with respect to initial rhythm, electrocardiographic patterns, myocardial infarction as underlying cause, neurological outcome, as well as clinical and laboratory markers. Clinical follow-up will be performed at 6 and 12 months. Safety end points include bleeding and stroke. CONCLUSION: The TOMAHAWK trial will address the unresolved issue of timing and general indication of angiography after OHCA without ST-segment elevation.

Right heart failure (RHF) because of pulmonary hypertension (PH) is a frequently encountered clinical problem with high mortality. The last resort, if pharmacological therapy fails, is mechanical circulatory support. There is a lack of percutaneous systems to support the right ventricle (RV). Venoarterial extracorporeal membrane oxygenation is widely used as a bailout in acute RHF in non-left ventricular assist device patients. Venoarterial extracorporeal membrane oxygenation does not unload the left ventricle and may cause failure of the left ventricle if used for a longer period of time. We report the long-term use of an ECMO-based percutaneous right ventricular assist system (oxyRVAD) capable to deliver up to 6 L/min of blood flow with a returning cannula placed in the main pulmonary artery used in RHF originating from PH with poor oxygenation. We present a series of four patients on oxyRVAD (mean treatment duration 15 ± 7.6 days). Patients benefited from the system clinically; however, two patients eventually died while on oxyRVAD. Nevertheless, we provide a proof-of-concept of this system in PH patients, which is feasible and might provide a useful "bridge-to-recovery" or "bridge-to-transplant" option in the management of patients with severe RHF because of PH.

Background: Veno-venous extracorporeal membrane oxygenation (vV-ECMO) is increasingly used as a rescue therapy in severe respiratory failure. In patients with pre-existent lung diseases or persistent lung injury weaning from vV-ECMO can be challenging. This study sought to investigate outcomes of patients transferred to a specialized ECMO center after prolonged ECMO therapy. Methods: We performed a retrospective analysis of all patients treated at our medical intensive care unit (ICU) between 01/2013 and 07/2016 who were transferred from an external ICU after > 8 days on vV-ECMO. Results: We identified 10 patients on ECMO for > 8 days. Prior to transfer, patients underwent ECMO therapy for 18 (9 – 34) ± 9.5 days. Total time on ECMO was 46 (16 – 135) ± 33 days. 9/10 patients were weaned from ECMO in the first 28 days after transfer, 7 after at least partial lung recovery, 2 after salvage lung transplant (10 ± 8.3 ECMO-free days at day 28). No patient died or needed re-initiation of ECMO therapy at day 28. Conclusion: Weaning from vV-ECMO was feasible even after prolonged ECMO courses and salvage lung transplant could be avoided in most cases. Patients may benefit from transfer to a specialized ECMO center.

Introduction: Extracorporeal CO 2 removal (ECCO 2 R) is increasingly used as a therapeutic strategy in hypercapnic lung failure in order to avoid intubation, to allow lung protective ventilator settings, or to facilitate weaning from invasive ventilation. Here, we report on the Homburg Lung, a novel minimal-invasive mid-flow ECCO 2 R system which was established and successfully used at our ICU. The Homburg Lung is a pump-driven (Maquet Rotaflow) system for veno-venous ECCO 2 R with ¼” tubing and a 0.8 m 2 surface oxygenator (Maquet Quadrox-I pediatric). Vascular access is usually established via a 19F/21cm bilumen cannula in the right internal jugular vein. Methods: To analyse efficacy and safety of the Homburg Lung, we screened our patient registry for ECCO 2 R procedures since 2013. Patients who underwent ECMO prior to ECCO 2 R were excluded. Patients who underwent ECCO 2 R more than one time since 2013 were only included once. Results: A total of 19 patients (age 52.3 ± 12.86 years, 42.1% female) was analysed. Ventilatory failure occurred due to COPD (47.4%), cystic fibrosis (21 %), and other origins (31.6%). The system generated a blood flow of 1.23 ± 0.29 lpm. Gas flow was 5.37 ± 2.98 lpm. Within 4 h, pCO 2 could be reduced from 74.03 ± 17.51 mmHg to 55.53 ± 10.85 mmHg. Cannulation-associated complications were transient arrhythmia (1/19 patients), pneumothorax (1/19), and air embolism (1/19). Fatal complications were not registered. Conclusion: The Homburg Lung provides effective CO 2 removal in hypercapnic lung failure. The cannulation is a safe procedure with complication rates comparable to those in central venous catheter implantation.

Eine Behandlung mit Tumor-Nekrose-Faktor-(TNF-)α-blockierenden Substanzen wird bei einer Reihe von Autoimmunerkrankungen eingesetzt. Dabei werden bei der Anti-TNF-α-Therapie der rheumatoiden Arthritis gelegentlich die Bildung von Autoantikorpern sowie lupusartige Syndrome beobachtet, selten kommt es auch zur Induktion von Glomerulonephritiden. Die Autoren berichten erstmals uber die Entwicklung eines systemischen Lupus erythematodes mit renaler Beteiligung bei einem Patienten mit Psoriasisarthritis unter einer Therapie mit dem loslichen TNF-α-Rezeptor Etanercept. Ein 70-jahriger Patient mit langjahriger Psoriasisarthritis entwickelte unter einer Therapie mit Etanercept eine Pleuritis, Perikarditis sowie ausgepragte Arthralgien. In den Laboruntersuchungen fanden sich bei deutlich erhohten Entzundungsparametern antinukleare Antikorper (ANA), eine Proteinurie von 3,2 g/Tag, eine leicht eingeschrankte Nierenfunktion sowie ein nephritisches Harnsediment. In einer daraufhin durchgefuhrten Nierenbiopsie wurde eine fokale proliferative Lupusnephritis diagnostiziert. Nach Absetzen von Etanercept und Einleitung einer Cyclophosphamidpulstherapie in Kombination mit oralen Steroiden normalisierten sich die Entzundungsparameter und die Nierenfunktion rasch, die Pleuritis und Perikarditis waren nicht mehr nachweisbar. Eine Anti-TNF-α-Therapie kann bei Patienten mit Psoriasisarthritis zur Induktion eines systemischen Lupus mit renaler Beteiligung fuhren.

152 consecutive patients with myocarditis according to the quantitative World Heart Federation Criteria (> 14 infiltrating cells/mm 2 by endomyocardial biopsy(EMB)) were analysed for cardiotropic agents. In 90 pts parvoviruses B19 (59,5%) and in 36 pts adenoviruses (23,8%) were assessd by PCR as causative viral pathogens. All virus positive patients were treated with 10 g/day Pentaglobin® i. v.(enriched IgG, IgA and IgM preparation, Biotest) at day 1 and 3. After six months all patients were reevalutated clinically, 73 patients (48%) in addition by EMB. Methods: We compared the following parameters before and after therapy: left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), shortening fraction (SF) by transthoracic echocardiography and LVEF or the left ventricular end-diastolic volume index (LVEDVI) using angiography. For exercise capacity we evaluated exercise ECG by treadmill test and clinical parameters according to the NYHA classification, before and after therapy. Results: After Pentaglobin therapy, all patients demonstrated a significant clinical improvement of the NYHA class, of exercise capacity and of LVEF (from 54,4 to 60,0%, p Conclusion: Treatment with an intermediate dose of Pentaglobin is highly effective in resolving myocardial inflammation independent of the underlying viral etiology, but it eradicates adenoviral much better than Parvo B19 infection.

Treatment with tumor necrosis factor-(TNF-)alpha-blocking agents is used in a variety of autoimmune diseases. In anti-TNF-alpha therapy for rheumatoid arthritis, occasionally, the development of autoantibodies as well as lupus-like syndromes have been observed, rarely, glomerulonephritides are also induced. The authors first report the development of lupus erythematosus with renal involvement in a patient with psoriatic arthritis during therapy with the soluble TNF-alpha receptor etanercept.A 70-year-old patient with long-standing psoriatic arthritis developed pleuritis, pericarditis, as well as marked arthralgias during therapy with etanercept. Laboratory investigation showed markedly increased parameters of inflammation, antinuclear antibodies (ANA), a proteinuria of 3.2 g/day, mild impairment of renal function, as well as a nephritic urinary sediment. A subsequently performed renal biopsy was diagnostic for focal proliferative lupus nephritis. After withdrawal of etanercept and initiation of a cyclophosphamide pulse therapy in combination with oral steroids, parameters of inflammation and renal function rapidly normalized; pleuritis and pericarditis were not detectable anymore.Anti-TNF-alpha therapy in patients with psoriatic arthritis or other autoimmune diseases may lead to induction of systemic lupus with renal involvement.

Introduction: Even though bleeding and thromboembolic events are major complications of extracorporeal membrane oxygenation (ECMO), data on the incidence of venous thrombosis (VT) and thromboembolism (VTE) under ECMO are scarce. Aims and objectives: This study analyzes the incidence and predictors of venous thrombosis and thromboembolism in patients treated with ECMO due to respiratory failure. Methods: Retrospective analysis of 102 patients treated on ECMO in our center from 04/2010 to 11/2015. Patients with thromboembolic events prior to admission were excluded. Diagnosis was made by imaging in survivors and postmortem examination in deceased patients. Results: We identified 42 survivors and 21 autopsy cases (mean age 46.0 ± 14.4 years; 37 (58.7%) male). 34 patients (54.0%) underwent ECMO therapy due to ARDS, 29 Patients (46.0%) with chronic organ failure were bridged to lung transplantation. Despite systemic anticoagulation at a mean PTT of 50.6 ± 12.8 s, (VT/VTE 47.0 ± 12.3 s and no VT/VTE 53.63 ± 12.51 s (P = 0.037)), VT and/or VTE were observed in 29 cases (46.1%). The rate of V. cava thrombosis was 15/29 (51.7%). Diagnosis of pulmonary embolism prevailed in deceased patients (5/21 (23.8%) versus 2/42 (4.8%) (P= 0.036). In a multivariable analysis only aPTT and time on ECMO predicted VT/VTE. There was no difference in the incidence of clinically diagnosed VT in ECMO survivors and autopsy findings. Conclusions: Venous thrombosis and thromboembolism following ECMO therapy are frequent and might influence outcome. Quality of anticoagulation and ECMO runtime predicted thromboembolic events. Current aPTT recommendations might be too low.